<?xml version="1.0" encoding="utf-8" standalone="yes"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Press Release on BEHIND-MS</title>
    <link>https://www.behind-ms.eu/en/tags/press-release/</link>
    <description>Recent content in Press Release on BEHIND-MS</description>
    <generator>Hugo</generator>
    <language>en</language>
    <lastBuildDate>Fri, 01 Dec 2023 00:00:00 +0000</lastBuildDate>
    <atom:link href="https://www.behind-ms.eu/en/tags/press-release/index.xml" rel="self" type="application/rss+xml" />
    <item>
      <title>First Announcement</title>
      <link>https://www.behind-ms.eu/en/news/first-announcement/</link>
      <pubDate>Fri, 01 Dec 2023 00:00:00 +0000</pubDate>
      <guid>https://www.behind-ms.eu/en/news/first-announcement/</guid>
      <description>&lt;p&gt;See also: &lt;a href=&#34;https://www.eurekalert.org/news-releases/1010132&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;eurekalert&lt;/a&gt;&#xA;&lt;/p&gt;&#xA;&lt;h2 id=&#34;background&#34;&gt;Background&lt;/h2&gt;&#xA;&lt;p&gt;The progression of multiple sclerosis (MS) can usually be slowed down with&#xA;medication, but a cure is currently not possible. It is now established that Epstein-Barr&#xA;virus is involved in the development of MS. However, it is not known how the&#xA;pathogen triggers the disease.&lt;/p&gt;&#xA;&lt;h2 id=&#34;eu-funding&#34;&gt;EU funding&lt;/h2&gt;&#xA;&lt;p&gt;The European Union is now funding the international research consortium BEHIND-MS as part of its HORIZON Europe programme, which&#xA;aims to clarify these associations in order to identify specific biomarkers and targeted&#xA;therapeutic approaches. The consortium, led by the German Cancer Research Center,&#xA;will receive 7.1 million euros over a period of five years.&lt;/p&gt;</description>
    </item>
  </channel>
</rss>
